Abstract 388P
Background
More and more evidences suggest that circulating tumor cells (CTC) may be a good biomarker, not only as a prognostic indicator for tumors, but also for monitoring therapeutic effect and recurrence. However, the detection of CTC usually requires the final artificial judgment. This requires experienced pathologists and increases their workload. The application of machine learning in medical image recognition can effectively improve the level of automation and reduce the workload. So we hope to use machine learning to identify CTCs.
Methods
First, the python's openCV software package is used to segment the images of CTCs by image denoising, image filtering, edge detection, image expansion and contraction techniques. Secondly, the segmented cell images as a training set are trained using the CNN deep learning network. The CNN deep learning network includes input layer, intermediate hidden layer, and output layer. The middle hidden layer contains three layers, namely layer1, layer2 and lager3. Each intermediate hidden layer further includes convolution layer, excitation layer, and pooling layer. After the input layer, the cell images first enter the first intermediate hidden layer. The convolution layer of the first intermediate hidden layer is composed of 32 5x5 convolution kernels, which are then output to the pooling layer for dimension reduction through the ReLU excitation layer. After dimension reduction, the data is output from the first hidden layer to complete an entire feature extraction process. Then, through the second and third intermediate hidden layers in sequence, all feature extraction is completed. Finally, it enters the output layer and output the result, ie, CTCs or non-CTCs.
Results
We took 2920 cells from 732 patients for training and testing. Among them, 2000 cells were used as training set and 920 cells were used as testing set. The sensitivity and specificity of recognition reached 86.1% and 84.5%, respectively.
Conclusions
To identify CTC by machine learning can reach high sensitivity and specificity. We are further revising our methods of deep learning to achieve greater recognition effect.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract